Vera Therapeutics is trading at $32.30, up +6.43% during the August 6, 2026 session, with the move potentially reflecting positioning around scheduled second-quarter results.
- Results were scheduled for August 6; analysts expected a $1.58-per-share loss and zero revenue.
- Broader indexes were mixed, offering no clear market-wide explanation.
- The gain may also reflect a delayed reaction to the July FDA approval.